Is Evenity a Bisphosphonate?

Bisphosphonates have long been the foundation of osteoporosis treatment, with millions of postmenopausal women in the U.S. using them to help slow bone loss, preserve bone density, and reduce fracture risk. These medications work by inhibiting bone resorption, but not all therapies for osteoporosis function in the same way.

Evenity (romosozumab-aqqg), approved for postmenopausal women at high risk of fractures, offers a different approach. Unlike bisphosphonates, Evenity is a monoclonal antibody that both stimulates new bone formation and reduces bone breakdown by blocking the protein sclerostin. This dual mechanism sets Evenity apart from traditional treatments.

In this article, we’ll explore whether Evenity is a bisphosphonate, explain its unique mechanism of action, and highlight how it differs from other osteoporosis therapies.

Key Takeaways

• Evenity is a monoclonal antibody, not a bisphosphonate, with a dual mechanism that stimulates bone formation and moderately reduces bone resorption.
• Unlike bisphosphonates, which primarily slow bone loss, Evenity actively builds new bone.
• Evenity is typically prescribed for a 12-month course, after which patients must transition to antiresorptive therapies such as bisphosphonates or denosumab to maintain bone density.
• Patient education is critical, as understanding Evenity’s mechanism and its cardiovascular risks, as well as post-treatment transitions, helps ensure adherence and optimal outcomes.

About: Doctor Medica is your trusted supplier of top-quality dermal fillers, viscosupplements, and more for your medical practice. We offer genuine products from leading brands at the lowest prices available. If you’re looking to order Evenity online for your practice, contact Doctor Medica today.  

Pharmacologic Classification: Monoclonal Antibody vs Bisphosphonate Mechanism

Many patients may ask, “Is Evenity a bisphosphonate?” The simple answer is no. Bisphosphonates, like alendronate, inhibit the cells responsible for bone resorption (osteoclasts). This reduces the breakdown of bone, preserving bone density over time. 

In contrast, Evenity (romosozumab-aqqg) is a monoclonal antibody that targets sclerostin, a protein that inhibits the Wnt signaling pathway, which is crucial for bone formation. By blocking sclerostin, Evenity actively promotes osteoblast activity, stimulating new bone formation.

This difference in mechanisms is what sets Evenity apart from bisphosphonates. Evenity doesn’t just slow bone loss; it also builds new bone while preventing its breakdown, making it an anabolic osteoporosis therapy. This makes Evenity especially beneficial for high-risk postmenopausal women who need rapid improvements in bone mineral density (BMD).

Dual Anabolic and Antiresorptive Actions of Romosozumab Compared with Osteoclast Inhibition

Romosozumab is unique among osteoporosis therapies because it combines two mechanisms that target both bone formation and bone resorption. Unlike bisphosphonates, romosozumab is an anabolic agent that actively stimulates bone formation while also maintaining some antiresorptive activity. This dual mechanism of action makes Evenity particularly valuable for patients at high risk of fractures, especially those with severe bone loss or previous fractures.

1. Anabolic Effect: Romosozumab stimulates osteoblasts to produce new bone tissue, thereby increasing bone mineral density (BMD), particularly in high-risk areas such as the spine and hip. This bone-building effect helps rebuild skeletal strength and improve bone structure in patients with advanced osteoporosis.
   
2. Antiresorptive Effect: While its primary function is to stimulate bone formation, romosozumab also moderately suppresses osteoclast-mediated resorption, which helps protect newly formed bone and ensures the structural integrity of the skeleton.

Rapid Improvements

Clinical studies show that romosozumab leads to faster increases in bone mineral density compared to bisphosphonates. This results in earlier protection against fractures, which is especially important for high-risk patients.

Monitoring via Bone Turnover Markers

Physicians use markers like P1NP (a bone formation marker) and CTX (a bone resorption marker) to assess the balance between bone formation and bone resorption during treatment, ensuring that patients are on the right therapy and can continue with an effective Evenity dosing schedule.

Clinical Positioning of Evenity in the Osteoporosis Treatment Sequence

Evenity is often reserved for postmenopausal women at high risk of fractures, as well as patients with severe osteoporosis. This therapy focuses on rapid bone formation during the 12-month treatment period, providing early gains in bone mineral density. The goal is to provide a strong foundation before transitioning to long-term maintenance therapies, ensuring patients receive optimal protection against fractures while minimizing the risk of further bone loss.

Treatment sequencing with Evenity typically starts with monthly dosing for 12 months to stimulate osteoblast activity and improve skeletal strength. Once this anabolic phase is complete, the patient transitions to antiresorptive therapies, such as bisphosphonates (alendronate, risedronate) or monoclonal antibodies (denosumab, Prolia). This approach ensures the bone gains made during the initial Evenity treatment phase are preserved and that fracture risk continues to decline over time.

Ongoing monitoring of bone mineral density is crucial during this process. Physicians regularly evaluate patient response with DXA scans and may also monitor bone turnover markers to guide further treatment decisions. This careful approach ensures that the benefits of Evenity are maintained, and that post-treatment bone loss is minimized, promoting long-term skeletal health and reducing fracture risk.

Key Counseling Points When Distinguishing Evenity from Bisphosphonates for Patients

Patient education plays a crucial role in the effective use of Evenity, especially for those who may be more familiar with bisphosphonates. Understanding the differences between these therapies helps patients make informed decisions, feel confident about their treatment plans, and better manage side effects. 

• Mode of Action: Evenity builds new bone through its anabolic effect, while bisphosphonates primarily prevent bone loss by inhibiting osteoclasts (bone-resorbing cells).
  
• Duration of Therapy: Evenity is typically prescribed for a 12-month course, whereas bisphosphonates may be used for several years for ongoing fracture prevention.
  
• Administration: Evenity is delivered as monthly subcutaneous injections, whereas bisphosphonates are usually taken orally or through intravenous infusions.
  
• Side Effects: Evenity carries a cardiovascular risk warning, while bisphosphonates can cause gastrointestinal irritation, atypical fractures, or osteonecrosis of the jaw (ONJ). It’s important to note that both classes of drugs carry a low risk of atypical femoral fractures (AFF) and osteonecrosis of the jaw (ONJ). However, these risks are more commonly associated with bisphosphonates.

Understanding these differences empowers patients to make informed decisions about their osteoporosis management. Discussing how long Evenity stays in your system and what to expect after the treatment course reinforces the importance of transitioning to bisphosphonates or denosumab for ongoing bone preservation.

Conclusion

Evenity is a monoclonal sclerostin antibody, not a bisphosphonate, with both anabolic and modest antiresorptive activity. This unique mechanism of action stimulates new bone formation, resulting in rapid improvements in bone mineral density. For postmenopausal women and patients at high fracture risk, Evenity provides an effective short-term strategy to strengthen bones before transitioning to long-term maintenance therapy.

Proper dosing and careful treatment sequencing are essential to sustaining bone density gains. After completing the 12-month course, transitioning to an antiresorptive therapy is necessary to preserve bone density and minimize post-treatment bone loss. Patient education, regular monitoring, and adherence to follow-up plans ensure optimal outcomes. By combining early anabolic effects with long-term maintenance, Evenity helps reduce fracture risk and supports lasting skeletal health.

FAQs

1. Is Evenity a bisphosphonate?

No, Evenity is a monoclonal antibody targeting sclerostin, stimulating bone formation rather than inhibiting osteoclasts like bisphosphonates.

2. How does Evenity differ from bisphosphonates?

Evenity has dual effects. It builds new bone and moderately reduces resorption. Bisphosphonates only slow bone loss by inhibiting osteoclasts.

3. How long is Evenity treatment prescribed?

Typically, Evenity is given for 12 months, followed by antiresorptive therapy to maintain bone density.

4. Can patients switch between Evenity and bisphosphonates?

Yes, treatment sequencing involves starting with Evenity for bone formation, then transitioning to bisphosphonates or other antiresorptives to preserve gains.

References

Langdahl BL, Andersen JD. Treatment of Osteoporosis: Unmet Needs and Emerging Solutions. J Bone Metab. 2018;25(3):133-140. doi:10.11005/jbm.2018.25.3.133

Deardorff WJ, Cenzer I, Nguyen B, Lee SJ. Time to benefit of bisphosphonate therapy for the prevention of fractures among postmenopausal women with osteoporosis. JAMA Internal Medicine. 2021;182(1):33. doi:10.1001/jamainternmed.2021.6745

Krupa KN, Parmar M, Delo LF. Romosozumab. StatPearls – NCBI Bookshelf. Published July 19, 2024. https://www.ncbi.nlm.nih.gov/books/NBK585139/

Liu L, Clifton-Bligh RJ, Girgis CM, Gild ML. Extending the therapeutic potential: Romosozumab in osteoporosis management. Journal of the Endocrine Society. 2024;8(11). doi:10.1210/jendso/bvae160